Study designDizajn studije
TRANSCEND-T2D-1 was a randomized, double-blind, placebo-controlled Phase III trial. It assigned 537 adults to once-weekly retatrutide or placebo. The primary endpoint was change in HbA1c at 40 weeks; body-weight change and safety were among the additional outcomes.TRANSCEND-T2D-1 bila je randomizovana, dvostruko slepa, placebom kontrolisana studija faze III. Uključila je 537 odraslih raspoređenih na retatrutid jednom nedeljno ili placebo. Primarni ishod bila je promena HbA1c nakon 40 nedelja; promena telesne mase i bezbednost bili su među dodatnim ishodima.
The publication reported improvements in glycaemic control and body weight in the studied population. Gastrointestinal adverse events were common, and the full paper should be consulted for dose-specific results, estimands, missing-data handling and adverse-event tables.Publikacija je prijavila poboljšanja glikemijske kontrole i telesne mase u proučavanoj populaciji. Gastrointestinalni neželjeni događaji bili su česti, a puni rad treba konsultovati za rezultate po dozama, estimande, obradu nedostajućih podataka i tabele neželjenih događaja.
Why it matters—and what it does not showZašto je važno—i šta ne pokazuje
A full peer-reviewed Phase III report carries more evidentiary detail than a company topline release. This 40-week monotherapy study still does not answer questions about rare or very long-term harms, cardiovascular outcomes, active-comparator performance or use outside its eligibility criteria. It is not regulatory approval.Puni recenzirani izveštaj faze III pruža više dokaznih detalja od preliminarnog saopštenja kompanije. Ova 40-nedeljna studija monoterapije ipak ne odgovara na pitanja o retkim ili veoma dugoročnim štetama, kardiovaskularnim ishodima, poređenju sa aktivnim lekom niti primeni van kriterijuma za uključivanje. Ona nije regulatorno odobrenje.